Off-Label Ltd

subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link
subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link
subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link
subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link
subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link
subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link
subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link
subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link

UK search results

Number of records found 31

Select ID for details Off-label therapeutic category Subcategory Drug Reported off-label use
2316 Central Nervous system Seizure Letrozole Treatment of sexual dysfunction due to low testosterone levels in a man with temporal lobe epilepsy (The authors additionally report that in this case study, letrozole in addition to standard antiseizure medication was also associated with improved seizure control)
3469 Endocrine & Metabolic Androgen disorder Letrozole In conjunction with follicle-stimulating hormone (FSH) for ovarian stimulation in patients with polycystic ovarian syndrome (PCOS) or ovulatory infertility receiving intrauterine insemination
253 Endocrine & Metabolic Developmental and deficiency Letrozole Adjunct therapy in the treatment of constitutional delay of puberty in boys*
4966 Endocrine & Metabolic Developmental and deficiency Letrozole Case report of the use of letrozole (2.5 mg daily) plus growth hormone (0.3 mg/kg weekly) to improve growth potential in a pubertal boy with growth hormone deficiency
5204 Endocrine & Metabolic Developmental and deficiency Letrozole Open label study to determine the effect of letrozole on delaying bone age progression, predicted adult height and adrenal gland function in adolescent males with limited growth potential
6331 Endocrine & Metabolic Androgen disorder Letrozole Randomized controlled trial to compare the efficacy of letrozole (2.5 mg daily) with that of clomifene citrate (100 mg daily) to induce ovulation in infertile patients with polycystic ovarian syndrome
5403 Endocrine & Metabolic Developmental and deficiency Letrozole Randomized controlled trial to investigate whether inhibition of oestrogen biosynthesis with the aromatase inhibitor, letrozole (2.5 mg daily), enables the achievement of near-final height in adolescent boys with constitutional delay of puberty
6250 Endocrine & Metabolic Androgen disorder Letrozole Randomized controlled trial to compare the effects of metformin plus letrozole (2.5 mg) with that of metformin plus clomiphene (100 mg) upon ovulatory response and pregnancy rate in women with polycystic ovary syndrome (SUBPOP)
7798 Malignant Disease Breast Letrozole Open label study to evaluate the activity of preoperative primary therapy with letrozole plus a GnRH analogue in thirty-five premenopausal women with T2-T4 N0-N2 breast cancer, whose tumours expressed oestrogen and progesterone receptors (The investigators conclude that preoperative letrozole in combination with a GnRH analogue is effective in premenopausal women)
7906 Malignant Disease Ovary Letrozole Phase II trial to evaluate the efficacy of letrozole (2.5 mg daily) in forty-two patients with estrogen receptor-positive relapsed ovarian cancer and a rising level of the tumour marker, CA125 (Out of thirty-three patients evaluable for radiological response, three (9%) had a partial remission, and fourteen (42%) had stable disease at twelve weeks)
8016 Malignant Disease Uterus Letrozole Case report of a thirty-six year old woman with recurrence of a low grade endometrial stromal sarcoma twelve years following surgery and adjuvant radiotherapy, which upon recurrence was managed with letrozole resulting in a partial response that was maintained at a thirty-nine month follow-up
5249 Malignant Disease Breast Letrozole Case reports of the use of leuprorelin plus either letrozole or anastrozole for the treatment of two men with oestrogen-and progesterone-receptor-positive, HER-2-negative metastatic breast cancer that in one patient failed to respond to either leuprorelin and anastrozole as single agent therapy, and in the other patient was refractory to treatment with paclitaxel, fluorouracil, doxorubicin and cyclophosphamide
5089 Malignant Disease Uterus Letrozole Single centre study to investigate the clinical and endocrine-related effects of a two-week preoperative course of treatment in patients with endometrial carcinoma of either letrozole (2.5 mg daily) or exemestane (25 mg daily)
1517 Malignant Disease Ovary Letrozole Relapsed epithelial ovarian cancer
1218 Malignant Disease Breast Letrozole Metastatic breast cancer in a male patient
4459 Malignant Disease Breast Letrozole Treatment of a male patient with locally advanced breast cancer
3498 Malignant Disease Uterus Letrozole Treatment of postmenopausal women with recurrent or advanced endometrial carcinoma
3632 Malignant Disease Uterus Letrozole First line hormonal therapy for the treatment of a patient with a recurrent low grade endometrial stromal sarcoma with a high expression of alpha oestrogen receptor (SUBPOP)
4201 Obstetrics & Gynaecology (incl male infertility) Infertility Letrozole Single dose treatment for ovarian stimulation
4203 Obstetrics & Gynaecology (incl male infertility) Infertility Letrozole Use of letrozole (5 mg daily on days 3 through 7 after menses) to control ovarian hyperstimulation in ovulatory infertile patients
4425 Obstetrics & Gynaecology (incl male infertility) Infertility Letrozole Controlled single blind trial to evaluate the adjunctive use of letrozole (2.5 mg daily from day 3-7) as part of an In Vitro Fertilization (IVF) protocol in women with a history of poor ovarian response receiving recombinant follicle-stimulating hormone (rFSH 75 IU daily on days 3 and 8)
3630 Obstetrics & Gynaecology (incl male infertility) Infertility Letrozole To investigate the effects of high dose (7.5 mg) daily treatment with letrozole upon superovulation in women with idiopathic infertility undergoing intrauterine insemination (IUI)
8780 Obstetrics & Gynaecology (incl male infertility) Uterus Letrozole Case series study to evaluate the efficacy of letrozole (2.5 mg daily for three months) as a primary therapy in five premenopausal women with endometrial hyperplasia with or without atypia (The investigators report that at the end of the treatment period curettage revealed no evidence of endometrial hyperplasia or atypia in any of the patients; they conclude that while aromatase inhibitors deserve attention for the conservative treatment of endometrial hyperplasia, more studies are necessary)
6397 Obstetrics & Gynaecology (incl male infertility) Infertility Letrozole Randomized controlled trial to evaluate the efficacy of letrozole as adjuvant therapy to recombinant follicle-stimulation hormone (FSH) in women with unexplained infertility undergoing controlled ovarian hyperstimulation
6466 Obstetrics & Gynaecology (incl male infertility) Infertility Letrozole Randomized pilot study to compare the results of intrauterine insemination under ovarian stimulation with either letrozole (5 mg daily) or human menopausal gonadotrophin
6468 Obstetrics & Gynaecology (incl male infertility) Infertility Letrozole Randomized pilot study to investigate the effect of adding letrozole to an ovarian stimulation protocol with recombinant follicle-stimulating hormone (FSH) and gonadotrophin-releasing hormone antagonist in women undergoing IVF or intracytoplasmic sperm injection treatment
7319 Obstetrics & Gynaecology (incl male infertility) Endometriosis Letrozole Case report of a middle-aged woman with endometriosis and severe pelvic pain after hysterectomy and bilateral salpingo-oopherectomy whose pain was not relieved following initial treatment with exemestane, but which was responsive to treatment with another aromatase inhibitor, letrozole (From this experience with this patient, the authors propose that patients with severe endometriosis may respond variably to different aromatase inhibitors)
7348 Obstetrics & Gynaecology (incl male infertility) Infertility Letrozole Randomized controlled trial of three doses of letrozole (2.5, 5 or 7.5 mg) for ovulation induction in patients with unexplained fertility (The investigators conclude that the use of higher doses of letrozole offers no advantage in terms of pregnancy rates over the lower (2.5 mg) dose)
6133 Obstetrics & Gynaecology (incl male infertility) Infertility Letrozole Prospective open label study to examine the efficacy of letrozole (2.5-5 mg daily) in ovulation induction when administered from day 3-7 of the menstrual cycle in infertile patients with an inadequate response to clomifene citrate
6195 Obstetrics & Gynaecology (incl male infertility) Infertility Letrozole Prospective non-randomized study to test the hypothesis that increasing the intraovarian androgen level using the aromatase inhibitor, letrozole together with chorionic gonadotrophin (hCG), enhances the sensitivity of follicles to follicle-stimulating hormone (FSH)
1993 Sexual Dysfunction Male Letrozole Treatment of sexual dysfunction due to low testosterone levels in a man with temporal lobe epilepsy (the authors additionally report that in this case study, letrozole in addition to standard antiseizure medication was also associated with improved seizure control)

Definition of descriptors (where appropriate):

*The reported drug was used as part of a combined therapy regimen

SUBPOP Variability in response may represent responding/nonresponding patient subgroups
ALERT Potential for remarkable and/or significant toxicity

 

 

 

About Us |Privacy Policy | Contact Us | ©2008 Off-Label Ltd